Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27573610 | 0.85 | MEN1 (0.50) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL28740747 | 0.80 | MEN1 (0.46) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL6081241 | 0.80 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL28740742 | 0.79 | MEN1 (0.44) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL6080100 | 0.77 | MEN1 (0.43) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL6080658 | 0.71 | MEN1 (0.38) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL634973 | 0.70 | ALOX15 (0.46) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL1963 | 0.70 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL6081528 | 0.69 | MEN1 (0.36) | MEN1KMT2AALDH1A1TSHRALOX15 | |
| SCHEMBL28822492 | 0.69 | MEN1 (0.46) | MEN1KMT2AALDH1A1TSHRCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| CN-101155791-A | Thiazolidinones for use as inhibitors of polo-like kinase (plk) | BAYER SCHERING PHARMA AG (DE) | 2008-04-02 | — | — | CN | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | MEN1 3850/4885KMT2A 849/4885ALDH1A1 3013/4885 |
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | MEN1 3800/4885KMT2A 3723/4885ALDH1A1 2553/4885 |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | PLK2, PLK4, PLK3 | MEN1 4624/4885KMT2A 3600/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.